Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Impaired cardiac microvascular function contributes to cardiovascular complications in diabetes. Glucagon-like peptide-1 (GLP-1) exhibits potential cardioprotective properties in addition to its glucose-lowering effect. This study was designed to evaluate the impact of GLP-1 on cardiac microvascular injury in diabetes and the underlying mechanism involved. Experimental diabetes was induced using streptozotocin in rats. Cohorts of diabetic rats received a 12-week treatment of vildagliptin (dipeptidyl peptidase-4 inhibitor) or exenatide (GLP-1 analog). Experimental diabetes attenuated cardiac function, glucose uptake, and microvascular barrier function, which were significantly improved by vildagliptin or exenatide treatment. Cardiac microvascular endothelial cells (CMECs) were isolated and cultured in normal or high glucose medium with or without GLP-1. GLP-1 decreased high-glucose–induced reactive oxygen species production and apoptotic index, as well as the levels of NADPH oxidase such as p47phox and gp91phox. Furthermore, cAMP/PKA (cAMP-dependent protein kinase activity) was increased and Rho-expression was decreased in high-glucose–induced CMECs after GLP-1 treatment. In conclusion, GLP-1 could protect the cardiac microvessels against oxidative stress, apoptosis, and the resultant microvascular barrier dysfunction in diabetes, which may contribute to the improvement of cardiac function and cardiac glucose metabolism in diabetes. The protective effects of GLP-1 are dependent on downstream inhibition of Rho through a cAMP/PKA-mediated pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [444]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 receptor (GLP-1R) is widely expressed in islet cells, kidney, lung, brain, and, interestingly, heart (6,7).”
BackgroundCoronary Microvascular Dysfunction
Camici, P. G., & Crea, F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra061889 · Cited by 1,605
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 1×
“Accumulating evidence has demonstrated that microvascular injury plays a very important role in the diabetic cardiovascular dysfunction (4,5).”
BackgroundCoronary Microvascular Dysfunction
Crea, F., Lanza, G. A., & Camici, P. G. (2014) · Springer eBooks · doi:10.1007/978-88-470-5367-0 · Cited by 1,287
The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism
Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., et al. (2005) · Nature · doi:10.1038/nature03967 · Cited by 995 · cited 1×
“Complete viral vectors were generated by homologous recombination with the AdEASY vector as described (27).”
MethodNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 1×
“Furthermore, a study of diabetic patients found that infusion of GLP-1 was associated with improved endothelial function (9).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“For example, GLP-1 is capable of protecting the heart against ischemia/reperfusion injury (38).”
BackgroundThe Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 5×
“To assess the potential role of intact GLP-1, DPP-4 inhibitors such as vildagliptin and GLP-1 analog exenatide are used as a means of preventing its degradation.”
BackgroundInfluentialExenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550 · cited 1×
“It has been shown that administration of GLP-1 at the time of reperfusion was effective in decreasing myocardial infarct size in patients with acute myocardial infarction (8).”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“443 These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid pro fi les, 444 preserving endothelial integrity and regulating endothelial function, 445 as well as modulating in fl ammatory processes.”
BackgroundMacro‐ and microvascular endothelial dysfunction in diabetes: 糖尿病诱导的内皮细胞功能损伤
Shi, Y., & Vanhoutte, P. M. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12521 · Cited by 545
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
“Our previous study identified Nox4 as a source for intracellular ROS overproduction [41].”
BackgroundSelf-citationYang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
Self-citationRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Xin, C., Liu, J., Zhang, J., Zhu, D., Wang, H., Xiong, L., Lee, Y., Ye, J., Lian, K., Xu, C., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.199 · Cited by 248
Self-citationNiccoli, G., Montone, R. A., Ibanez, B., Thiele, H., Crea, F., Heusch, G., Bulluck, H., Hausenloy, D. J., Berry, C., Stiermaier, T., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315344 · Cited by 224
Zhu, D., Wang, H., Zhang, J., Zhang, X., Xin, C., Zhang, F., Lee, Y., Zhang, L., Lian, K., Yan, W., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.07.015 · Cited by 212
Self-citationEffects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“These effects were inhibited after treatment with GLP-1 (10 nmol/L); an increased cAMP/PKA and decreased Rho expression were also demonstrated in this study [117].”
BackgroundMa, S., Feng, J., Zhang, R., Chen, J., Han, D., Li, X., Yang, B., Li, X., Fan, M., Li, C., et al. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4602715 · Cited by 201
“(18)F-Fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) scanning was performed using an animal PET/CT scanner (Mediso Nano PET/CT, Mediso Medical Imaging Systems, Budapest, Hungary) to evaluate cardiac glucose metabolism as described previously [24].”
MethodSelf-citationZhang, Y., Zhou, H., Wu, W., Shi, C., Hu, S., Yin, T., Ma, Q., Han, T., Zhang, Y., Tian, F., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.03.035 · Cited by 189
Zhou, H., Shi, C., Hu, S., Zhu, H., Ren, J., & Chen, Y. (2018) · Angiogenesis · doi:10.1007/s10456-018-9611-z · Cited by 170
Self-citationMST1 coordinately regulates autophagy and apoptosis in diabetic cardiomyopathy in mice
Zhang, M., Zhang, L., Hu, J., Lin, J. M., Wang, T., Duan, Y., Man, W., Feng, J., Sun, L., Jia, H., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4070-9 · Cited by 145
Self-citationCardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
“GLP-1R protein has also been detected in human coronary artery endothelial cells (HCAEC) and human umbilical vein endothelial cells (HUVEC) [33,34].”
BackgroundBadawi, G. A., Fattah, M. A. A. E., Zaki, H. F., & Sayed, M. I. E. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0331-6 · Cited by 127
Balteau, M., Van Steenbergen, A., Timmermans, A. D., Dessy, C., Behets-Wydemans, G., Tajeddine, N., Castanares-Zapatero, D., Gilon, P., Vanoverschelde, J.-L., Horman, S., et al. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00210.2014 · Cited by 121
Meng, Z., Liu, X., Li, T., Fang, T., Cheng, Y., Han, L., Sun, B., & Chen, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107492 · Cited by 128
Ursolic acid ameliorates oxidative stress, inflammation and fibrosis in diabetic cardiomyopathy rats
Wang, X.-T., Yan Fang, G. O. N. G., Zhou, B., Yang, J., Cheng, Y., Zhao, J., & Qi, M.-Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.032 · Cited by 117
Godinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
Schlegel, N., & Waschke, J. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1755-y · Cited by 101
“Similarly, when endothelial barrier function is compromised under more complex pathophysiologic conditions, such as in experimental diabetes or after hypoxia-reoxygenation, glucagon-likepeptide-1 (GLP-1) or cAMP analogs restore endothelial barrier properties (Aslam et al. 2013; Wang et al. 2013).”
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
“STZ-induced diabetic rats exenatide or vildagliptin 12 weeks protection of endothelial barrier function by both drugs (at transmission electron microscopy) [226]”
BackgroundMethodInfluentialAre targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 102
Hu, J., Wang, S., Xiong, Z., Cheng, Z., Yang, Z. P., Lin, J. M., Wang, T., Feng, X., Gao, E., Wang, H., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.026 · Cited by 97
Self-citationPerspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
Wu, L., Wang, K., Wang, W., Wen, Z., Wang, P., Liu, L., & Wang, D. W. (2018) · Aging Cell · doi:10.1111/acel.12763 · Cited by 92
Self-citationEid, R. A., Bin-Meferij, M. M., El-kott, A. F., Eleawa, S. M., Zaki, M. S. A., Al-Shraim, M. M., El-Sayed, F., Eldeen, M. A., Alkhateeb, M. A., Alharbi, S., et al. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09984-5 · Cited by 97
GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells
Li, Q., Lin, Y., Wang, S., Zhang, L., & Guo, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-06712-z · Cited by 87
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó, R., & Hernández, C. (2017) · Diabetes · doi:10.2337/db16-1364 · Cited by 86
“(33) have shown that GLP-1(9-36)amide normalizes ROS production and its pathophysiological consequences in cultured endothelial cells and in mice after transient hyperglycemia.”
BackgroundInfluentialDiabetic Vasculopathy: Macro and Microvascular Injury
Mota, R. I., Morgan, S. E., & Bahnson, E. M. (2020) · Current Pathobiology Reports · doi:10.1007/s40139-020-00205-x · Cited by 92
Wang, Z., Yan, Z., Wang, F., Cai, J., Guo, L., Su, J., & Liu, Y. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.05.011 · Cited by 83
“Thus, abnormal protein phosphorylation and aberrant protein kinase activities are closely coupled with many diseases, such as some neurodegenerative diseases, cancers and diabetes (Beristain et al., 2015; Chen et al., 2012; Myeku et al., 2016; Wang et al., 2013).”
BackgroundGuo, X., Xue, M., Li, C., Yang, W., Wang, S., Ma, Z.-J., Zhang, X., Wang, X., Zhao, R., Chang, B., et al. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.08.029 · Cited by 81
Hu, S.-Y., Zhang, Y., Zhu, P., Zhou, H., & Chen, Y.-D. (2017) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2017.01.008 · Cited by 87
Shen, M., Wang, L. Q., Wang, B., Wang, T., Yang, G., Shen, L., Wang, T., Guo, X., Liu, Y., Xia, Y., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.479 · Cited by 76
GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway
Ying, Y., Zhu, H., Liang, Z., Ma, X., & Li, S. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0155 · Cited by 72
“Recent studies have suggested that the PI3K/GSK3B/b-catenin signalling pathway shows potential anti-apoptotic effects after myocardial infarction (MI) in rat ischemic preconditioning (Kaga et al. 2006) or post-conditioning (Wu et al. 2012) models.”
BackgroundResultSelf-citationVascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Current status of NADPH oxidase research in cardiovascular pharmacology
Álvarez, E., Rodiño-Janeiro, Paradela-Dobarro, Castiñeiras-Landeira, Raposeiras‐Roubín, S., & González‐Juanatey, J. R. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33053 · Cited by 78
DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 62
Self-citationRenoprotective Effects of DPP-4 Inhibitors
Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., & Tanabe, M. (2021) · Antioxidants · doi:10.3390/antiox10020246 · Cited by 66
“GLP-1 induces anti-inflammatory effects by downregulating reactive oxygen species (ROS) generation in vascular cells [40,41] and renal cells [42,43].”
BackgroundZhao, L., Li, A. Q., Zhou, T. F., Zhang, M. Q., & Qin, X. M. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00151.2014 · Cited by 61
Peng, C., Ma, J., Gao, X. J., Tian, P., Li, W., & Zhang, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079739 · Cited by 60
“Generation of ROS in CMECs was visualized using the GENMED intracellular ROS red fluorescence determination kit (GENMED, Shanghai, China) according to the manufacturer’s instructions [22].”
Self-citationRetractedHan, F., Xue, M., Chang, Y., Li, X., Yang, Y., Sun, B., & Chen, L. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20485 · Cited by 59
On the potential of acarbose to reduce cardiovascular disease
Standl, E., Theodorakis, M. J., Erbach, M., Schnell, O., & Tuomilehto, J. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-81 · Cited by 65
“Thus, it seems reasonable to conclude that acarbose and other AGIs might enhance the potentially beneficial effects of GLP-1 on the CV system by increasing GLP-1 levels in a physiological manner [42,43].”
BackgroundLi, Z., Ni, C.-L., Yao, Z., Chen, L.-M., & Niu, W.-Y. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.008 · Cited by 56
Zhou, T., Zhang, M., Zhao, L., Li, A., & Qin, X. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00093.2016 · Cited by 54
Li, S., Wu, H., Han, D. H., Ma, S., Fan, W., Wang, Y., Zhang, R., Fan, M., Huang, Y., Fu, X., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3537609 · Cited by 54
Self-citationSukumaran, V., Tsuchimochi, H., Sonobe, T., Waddingham, M. T., Shirai, M., & Pearson, J. T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01000-z · Cited by 54
Faber, R., Zander, M., Pena, A., Michelsen, M. M., Mygind, N. D., & Prescott, E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0206-3 · Cited by 51
Ding, W., Chang, W.-G., Guo, X.-C., Liu, Y., Xiao, D.-D., Ding, D., Wang, J.-X., & Zhang, X.-J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00202 · Cited by 50
Lin, J. M., Zhang, L., Zhang, M., Hu, J., Wang, T., Duan, Y., Man, W., Wu, B., Feng, J., Sun, L., et al. (2016) · Scientific Reports · doi:10.1038/srep34199 · Cited by 51
Self-citationTomo, P. D., Lanuti, P., Pietro, N. D., BALDASSARRE, M. P. A., Marchisio, M., Pandolfi, A., Consoli, A., & Formoso, G. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2925 · Cited by 53
Ramos, H., Bogdanov, P. M., Sampedro, J., Huerta, J., Simó, R., & Hernández, C. (2020) · Antioxidants · doi:10.3390/antiox9090846 · Cited by 49
“obtained similar results with exendin-4 (GLP-1 receptor agonist) using human coronary artery endothelial cells [15,16].”
ResultChang, G., Liu, J., Qin, S., Jiang, Y., Zhang, P., Yu, H., Lu, K., Zhang, N., Cao, L., Wang, Y., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3318 · Cited by 48
Self-citationTang, S.-T., Tang, H.-Q., Su, H., Wang, Y., Zhou, Q., Zhang, Q., Wang, Y., & Zhu, H.-Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108667 · Cited by 48
Self-citationDPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 57
Chien, C.-T., Jou, M.-J., Cheng, T.-Y., Yang, C.-H., Yu, T.-Y., & Li, P.-C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.126 · Cited by 46
Soliman, M., Cho, E.-H., Park, J., Kim, J., Alfajaro, M. M., Baek, Y., Kim, D.-S., Kang, M.-I., Park, S., & Cho, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-32352-y · Cited by 49
Tang, S.-T., Zhang, Q., Tang, H.-Q., Wang, C.-J., Su, H., Zhou, Q., Wei, W., Zhu, H.-Q., & Wang, Y. (2016) · Endocrine · doi:10.1007/s12020-015-0852-y · Cited by 46
Self-citationIncretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
“of diabetic complications [23], are involved in the beneficial effects of GLP-1 on oxidative stress in endothelia cells [27] and the aorta [54] under diabetic conditions.”
BackgroundXu, J., Wei, G., Wang, J., Zhu, J., Yu, M., Zeng, X., Wang, H., Xie, W., & Kong, H. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0170-0 · Cited by 48
Self-citationArtunc-Ulkumen, B., Pala, H. G., Pala, E. E., Yavasoglu, A., Yigitturk, G., & Erbas, O. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.975686 · Cited by 45
“Recent studies have shown that exenatide has also protective effect against cardiac microvascular injury seen in DM [18,19].”
BackgroundGLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A
Dai, Y., Dai, D., Wang, X., Ding, Z., Li, C., & Mehta, J. L. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000087 · Cited by 44
“As shown in Figure 3A, PKI (6-22) amide significantly inhibited PKA activity and blocked the effect of nGLP-1 and liraglutide on the expression of CD36 (P , 0.05 vs. non-PKA inhibitor–treated cells) (Fig.”
BackgroundMethodInfluentialMetabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
Wang, D., Hou, J., Wan, J., Yang, Y., Liu, S., Li, X., Li, W.-Z., Dai, X., Zhou, P., Liu, W., et al. (2021) · Journal of International Medical Research · doi:10.1177/0300060520985363 · Cited by 47
Self-citationNielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43
Garczorz, W., Gallego‐Colon, E., Kosowska, A., Kłych‐Ratuszny, A., Woźniak, M., Marcol, W., Niesner, K. J., & Francuz, T. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12317 · Cited by 43
Functional blocking of Ninjurin1 as a strategy for protecting endothelial cells in diabetes mellitus
Wang, X., Qin, J., Zhang, X. Y., Peng, Z., Ye, K., Wu, X., Yang, X., Shi, H., Zhao, Z., Guo, X., et al. (2017) · Clinical Science · doi:10.1042/cs20171273 · Cited by 44
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
Molecular Basis of Impaired Glycogen Metabolism during Ischemic Stroke and Hypoxia
Hossain, M. I., Roulston, C. L., & Stapleton, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097570 · Cited by 44
Wang, Y., Zhang, J., Wang, Z., Wang, C., & Ma, D. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10224-y · Cited by 39
Self-citationSalheen, S. M., Panchapakesan, U., Pollock, C. A., & Woodman, O. L. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.02.003 · Cited by 42
GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes
Karakasis, P., Patoulias, D., Theofilis, P., Pamporis, K., Sagris, Μ., Vlachakis, P. K., Koufakis, T., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073050 · Cited by 42
“A potential explanation lies in the inhibition of the Rho/ROCK signaling axis, a key mediator of oxidative stress-induced endothelial damage [71].”
Lim, D.-M., Park, K.-Y., Hwang, W.-M., Kim, J.-Y., & Kim, B.-J. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4279 · Cited by 37
“The protective effects of GLP-1 are dependent on the downstream inhibition of Rho in a cAMP/Protein kinase A-dependent manner (25).”
Genetic Engineering of Mesenchymal Stem Cells for Regenerative Medicine
Nowakowski, A., Walczak, P., Janowski, M., & Lukomska, B. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0062 · Cited by 38
“GLP-1 is one of the factors that exhibit cardioprotective properties [159].”
Tsai, T.-H., Lee, C.-H., Cheng, C.-I., Fang, Y.-N., Chung, S.-Y., Chen, S.-M., Lin, C.-J., Wu, C.-J., Hang, C.-L., & Chen, W.-Y. (2019) · Cells · doi:10.3390/cells8060589 · Cited by 37
Karakasis, P., Fragakis, N., Patoulias, D., Theofilis, P., Sagris, Μ., Koufakis, T., Vlachakis, P. K., Rangraze, I. R., El‐Tanani, M., Tsioufis, K. P., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092112 · Cited by 41
“Additionally, research conducted on diabetic rats demonstrated that exenatide preserved cardiac microvascular integrity and reduced the diffusion of lanthanum nitrate across endothelial cells, highlighting its protective effects on cardiac microvascular barrier function [71].”
BackgroundYan, F., Zhang, G.-H., Feng, M. H., Zhang, W., Zhang, J., Dong, W., Zhang, C., Zhang, Y., Chen, L., & Zhang, M.-X. (2015) · Molecular Medicine · doi:10.2119/molmed.2014.00259 · Cited by 37
Huang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Peli1 induction impairs cardiac microvascular endothelium through Hsp90 dissociation from IRE1α
Zhao, Q., Yang, J., Chen, H., Li, J., Que, L., Zhu, G., Liu, L., Ha, T., Chen, Q., Li, C., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.017 · Cited by 36
Zhang, X., Duan, Y., Zhang, X., Jiang, M., Man, W., Zhang, Y., Wu, D., Zhang, J., Song, X., Li, C., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02887-7 · Cited by 36
Self-citationHamdi, Y., Kaddour, H., Vaudry, D., Leprince, J., Zarrouk, A., Hammami, M., Vaudry, H., Tonon, M., Amri, M., & Masmoudi‐Kouki, O. (2015) · Peptides · doi:10.1016/j.peptides.2015.06.010 · Cited by 37
Qi, Y., Du, X., Yao, X., & Zhao, Y. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1578783 · Cited by 35
“Preclinical animal studies have shown that administration of vildagliptin could improve vascular integrity and protect against diabetic conditioninduced vascular senescence in diabetic rats [24,25].”
BackgroundTate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…either saxagliptin or apogliptin had no significant effects on their primary composite end points of cardiovascular death, or non-fatal MI/stroke (Scirica et al., 2013; White et al., 2013), although it should be noted that SAVOR-TIMI 53 reported a 27% increase in hospitalization for heart failure.”
BackgroundCurrent concepts regarding developmental mechanisms in diabetic retinopathy in Taiwan
Chen, S., Hsu, Y., Lin, Y., Huang, Y.-C., Chen, C., Lin, W.-D., Liao, W.-L., Chen, Y., Lin, W., Liu, Y.-H., et al. (2016) · Biomedicine · doi:10.7603/s40681-016-0007-3 · Cited by 33
“GLP-1 improves -cell mass, promotes glucose disposal in streptozotocin-induced diabetic mice, and defends against cardiac microvascular injury of diabetes via a cAMP/PKA/Rho-dependent mechanism [47, 48] (Figure 1).”
BackgroundGao, P., Li, L., Wei, X., Wang, M., Hong, Y., Wu, H., Shen, Y., Ma, T., Wei, X., Zhang, Q., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13778 · Cited by 35
Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway
Yang, Y., Du, J., Xu, R., Shen, Y., Yang, D., Li, D., Hu, H., Pei, H., & Yang, Y. (2020) · Aging · doi:10.18632/aging.202159 · Cited by 33
Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation
Li, A. Q., Zhao, L., Zhou, T. F., Zhang, M. Q., & Qin, X. M. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00249.2014 · Cited by 32
Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 37
“However in one study, neonatal rat cardiomyocytes exposed to either high glucose concentrations or hydrogen peroxide showed that exendin-4 attenuated apoptosis without lowering ROS levels [109].”
BackgroundResultInfluentialWu, Q., Li, D., Huang, C., Zhang, G., Wang, Z., Liu, J., Yu, H., Song, B., Zhang, N., Li, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113517 · Cited by 34
Hwang, H., Jung, T. W., Ryu, J. Y., Hong, H. C., Choi, H. Y., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.04.017 · Cited by 34
“Recently, Wang et al. (2013) showed that GLP-1 decreases the induction of ROS and enhancement of the apoptotic index by high glucose in cardiac microvascular endothelial cells.”
Shi, J., & Huang, Q. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9085 · Cited by 40
“GLP-1 has also been reported to protect cardiac microvessels against oxidative stress and apoptosis, and suppress the development of microvascular barrier dysfunction, in diabetes by inhibiting Rho through a cyclic AMP/protein kinase A-mediated signaling pathway (15).”
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
“Treatment with GLP-1 at a concentration of 10 nmol/L mitigates these adverse effects by enhancing cAMP/PKA signaling and reducing Rho protein expression [119].”
Do incretins improve endothelial function?
Oyama, J., Higashi, Y., & Node, K. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-21 · Cited by 37
“oxidase and Rho-expression, with increases in the cAMP/ PKA activity in cardiac microvascular endothelial cells [12].”
BackgroundWang, D., Jiang, L., Feng, B., He, N., Zhang, Y., & Ye, H. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13098 · Cited by 32
Self-citationLin, C. D., Tona, F., & Osto, E. (2015) · International Journal of Endocrinology · doi:10.1155/2015/312848 · Cited by 33
Chen, F., He, L., Li, J., Yang, S., Zhang, B., Zhu, D., Wu, Z., Zhang, S., Hou, D., Ouyang, C., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.879294 · Cited by 32
Tsukamoto, M., Niimi, N., Sango, K., Takaku, S., Kanazawa, Y., & Utsunomiya, K. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1333-3 · Cited by 29
Ma, S., Zhang, Z., Yi, F., Wang, Y., Zhang, X., Li, X., Yuan, Y., & Cao, F. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/529173 · Cited by 28
Self-citationLi, Y., Huang, C., Fu, W., Zhang, H., Lao, Y., Zhou, H., Tan, H., & Xu, H. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112645 · Cited by 28
Pathological Roles of Oxidative Stress in Cardiac Microvascular Injury
Hou, J. W., Yuan, Y., Chen, P., Lu, K., Tang, Z., Liu, Q., Xu, W., Zheng, D., Xiong, S., & Pei, H. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101399 · Cited by 28
Zhang, Y., An, Y., Sun, L., Qu, H., Li, X., He, X., Wu, R., Chen, F., Tian, B., & Yin, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1152845 · Cited by 29
Metadata
- Authors
- Wang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., Wang, H., Ren, J., & Cao, F.
- Affiliations
- Xijing Hospital (CN)
- University of Wyoming (US)
- Corresponding author
- Cao, Feng
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 1697-1708
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3636622
- OpenAlex
- W2117213923
- Cited by
- 179
- References
- 54
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 12 · 2023: 6 · 2022: 13 · 2021: 11 · 2020: 11 · 2019: 15 · 2018: 9 · 2017: 21 · 2016: 16 · 2015: 21 · 2014: 22 · 2013: 7
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- glucagon-like peptide-1, vildagliptin, exenatide, DPP-4 inhibitors, cardiac microvascular endothelial cells, cAMP/PKA signaling, Rho, oxidative stress, apoptosis, NADPH oxidase, cardiac glucose metabolism, streptozotocin-induced diabetes
- MeSH terms
- Exenatide, Cyclic AMP, Animals, Cardiotonic Agents, Cells, Cultured, Diabetic Angiopathies, Disease Models, Animal, Endothelium, Vascular, Heart Ventricles, Hyperglycemia, Hypoglycemic Agents, Male, Peptides, Random Allocation, Venoms, Second Messenger Systems, Rats, Sprague-Dawley, Oxidative Stress, rho GTP-Binding Proteins, Rats, Glucagon-Like Peptide 1, AMP-Activated Protein Kinases, Microvessels, Diabetic Cardiomyopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.